Pharmaceutical

ESCMID 2024: Advances in drug resistance testing

Techniques such as rapid nanomotion-based susceptibility testing, and MALDI-TOF-MS could be used to identify resistance mechanisms of several deadly organisms.

May 5, 2024 - 00:00
ESCMID 2024: Advances in drug resistance testing
Techniques such as rapid nanomotion-based susceptibility testing, and MALDI-TOF-MS could be used to identify resistance mechanisms of several deadly organisms.
Read the original article

Tags:

Previous Article

Lexicon plans another bid for Zynquista in type 1 diabetes

Next Article

NHS to provide Pfizer’s Voxelotor to treat sickle cell disease

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Innate shelves lacutamab monotherapy plans in peripheral T cell lymphoma

Innate shelves lacutamab monotherapy plans in periphera...

Mar 24, 2024

FDA grants accelerated approval for PTC’s AADC deficiency gene therapy

FDA grants accelerated approval for PTC’s AADC deficien...

Nov 15, 2024

Amgen acquires Horizon Therapeutics for $27.8bn

Amgen acquires Horizon Therapeutics for $27.8bn

Oct 9, 2023